Aerovate Therapeutics Stock Investor Sentiment

AVTE Stock  USD 2.41  0.02  0.82%   
About 61% of Aerovate Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Aerovate Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Aerovate Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Aerovate Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
over six months ago at seekingalpha.com         
Disposition of 3432 shares by Benjamin Dake of Aerovate Therapeutics at 28.0068 subject to Rule 16b-...
seekingalpha News
over six months ago at finance.yahoo.com         
Aerovate Therapeutics Announces Full-Year 2023Financial Results and Business Highlights
Yahoo News
over six months ago at investing.com         
Aerovate Therapeutics shares target lifted to 65 by Jefferies
Investing News at Macroaxis
over six months ago at seekingalpha.com         
Aerovate Therapeutics reports FY results
seekingalpha News
over six months ago at gurufocus.com         
Chief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc
Gurufocus Stories at Macroaxis
over six months ago at gurufocus.com         
Insider Sell Aerovate Therapeutics Incs Chief Technical Officer Marinus Verwijs Sells ...
Gurufocus Stories at Macroaxis
over six months ago at news.google.com         
Acquisition by Marinus Verwijs of 5300 shares of Aerovate Therapeutics at 14.59 subject to Rule 16b-...
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of 2764 shares by Marinus Verwijs of Aerovate Therapeutics at 26.4558 subject to Rule 16...
Macroaxis News
over six months ago at www.macroaxis.com         
Disposition of 7581 shares by Benjamin Dake of Aerovate Therapeutics at 26.4825 subject to Rule 16b-...
Macroaxis News
over six months ago at news.google.com         
Aerovate Therapeutics Trading Up 5.2 percent - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Aerovate Therapeutics, Inc. Insider Sells 50440.32 in Stock - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Aerovate Therapeutics Shares Up 5.2 percent - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
George A. Eldridge Sells 2,016 Shares of Aerovate Therapeutics, Inc. Stock - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Disposition of 2016 shares by George Eldridge of Aerovate Therapeutics at 25.0223 subject to Rule 16...
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Disposition of 2051 shares by George Eldridge of Aerovate Therapeutics at 25.0461 subject to Rule 16...
news
Far too much social signal, news, headlines, and media speculation about Aerovate Therapeutics that are available to investors today. That information is available publicly through Aerovate media outlets and privately through word of mouth or via Aerovate internal channels. However, regardless of the origin, that massive amount of Aerovate data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aerovate Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aerovate Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aerovate Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aerovate Therapeutics alpha.

Aerovate Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Aerovate Stock analysis

When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Transaction History
View history of all your transactions and understand their impact on performance
CEOs Directory
Screen CEOs from public companies around the world
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Fundamental Analysis
View fundamental data based on most recent published financial statements
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences